Response and survival outcomes of daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD) induction in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients

被引：0

作者：

Joseph, Nisha ^{[1
]}

Kaufman, Jonathan ^{[1
]}

Lonial, Sagar ^{[1
]}

Hofmeister, Craig ^{[1
]}

Dhodapkar, Madhav ^{[1
]}

Gupta, Vikas ^{[1
]}

DiCamillo, Sara ^{[1
]}

Roberts, Danielle ^{[1
]}

Boise, Lawrence ^{[1
]}

Nooka, Ajay ^{[1
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-141

引用

页码：S113 / S113

页数：1

共 50 条

[21] A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study
Nooka, Ajay K.
Kaufman, Jonathan L.
Rodriguez, Cesar
Jakubowiak, Andrzej
Efebera, Yvonne
Reeves, Brandi
Wildes, Tanya
Holstein, Sarah A.
Anderson Jr, Larry D.
Badros, Ashraf
Shune, Leyla
Chari, Ajai
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter
FUTURE ONCOLOGY, 2022, 18 (40) : 4443 - 4456
[22] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: A multicenter retrospective comparative analysis
Nishimura, Noriko
Suzuki, Kazuhito
Tsukada, Nobuhiro
Nagata, Yasuyuki
Okaduka, Kiyoshi
Mishima, Yuko
Yokoyama, Masahiro
Nishiwaki, Kaichi
Ishida, Tadao
Yano, Shingo
Terui, Yasuhito
Suzuki, Kenshi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E214 - E215
[23] Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN.
Rodriguez, Cesar
Kaufman, Jonathan L.
Laubach, Jacob
Sborov, Douglas W.
Reeves, Brandi
Chari, Ajai
Silbermann, Rebecca Wang
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Bumma, Naresh
Jakubowiak, Andrzej J.
Orlowski, Robert Z.
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter M.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[24] Stem Cell (SC) Yield and Transplant with Daratumumab ± Bortezomib, Lenalidomide and Dexamethasone in Transplant-eligible Newly Diagnosed Multiple Myeloma Patients in the Phase 3 PERSEUS Study
Sonneveld, Pieter
Dimopoulos, Meletios
Boccadoro, Mario
Hang Quach
Ho, P. Joy
Beksac, Meral
Hulin, Cyrille
Antonioli, Elisabetta
Leleu, Xavier
Mangiacavalli, Silvia
Perrot, Aurore
Cavo, Michele
Belotti, Angelo
Broijl, Annemiek
Gay, Francesca
Mina, Roberto
van de Donk, Niels
Liu, Yanfang
Wang, Jianping
Sitthi-Amorn, Anna
de Boer, Carla J.
Carson, Robin
Rodriguez-Otero, Paula
Blade, Joan
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S246 - S246
[25] Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
Rosinol, Laura
Hebraud, Benjamin
Oriol, Albert
Colin, Anne-Laurene
Tamayo, Rafael Rios
Hulin, Cyrille
Blanchard, Maria Jesus
Caillot, Denis
Sureda, Anna
Hernandez, Miguel Teodoro
Arnulf, Bertrand
Mateos, Maria-Victoria
Macro, Margaret
San-Miguel, Jesus
Belhadj, Karim
Lahuerta, Juan Jose
Garelik, M. Brigid
Blade, Joan
Moreau, Philippe
FRONTIERS IN ONCOLOGY, 2023, 13
[26] Real-World Data on the Daratumumab Plus Bortezomib, Thalidomide and Dexamethasone Followed by Lenalidomide Maintenance for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
Crusoe, Edvan de Queiroz
Ribeiro, Glaciano
Moura, Fernanda
Costa, Abel
Aranha, Milton
Bittencourt, Rosane
Ribeiro, Eduardo
Neto, Jorge
Cunha, Rafael
Mattos, Ederson
Braga, Walter
Lima, Juliana Souza
Gusmao, Breno
Lopes, Danielle Ovigli
Berg, Luiza
Souto, Joao
Maiolino, Angelo
Hungria, Vania T. M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S223 - S223
[27] Reduction in disease symptoms/impacts after daratumumab, lenalidomide, bortezomib, and dexamethasone treatment for transplant-eligible patients with newly diagnosed multiple myeloma (GRIFFIN study)
Silbermann, Rebecca
Laubach, Jacob
Kaufman, Jonathan
Sborov, Douglas
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Costa, Luciano
Anderson, Larry
Nathwani, Nitya
Shah, Nina
Bumma, Naresh
Costello, Caitlin
Jakubowiak, Andrzej
Orlowski, Robert
Shain, Ken
Gries, Katharine
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Matt, Kathryn
Lin, Thomas
Usmani, Saad
Voorhees, Peter
Richardson, Paul
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S125 - S126
[28] Lenalidomide, Bortezomib, and Dexamethasone (RVD) As Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)
Joseph, Nisha
Almaula, Dhwani
Gleason, Charise
Heffner, Leonard
Boise, Lawrence H.
Kaufman, Jonathan L.
Lonial, Sagar
Nooka, Ajay
BLOOD, 2017, 130
[29] Real-world analysis of D-RVd v. RVd at induction for newly diagnosed transplant eligible multiple myeloma patients
Hydren, Jay R.
Sweeney, Nathan W.
Sborov, Douglas W.
Martinez, Jorge Arturo Hurtado
Perez, Patricia Alejandra Flores
Aldana, Ana M. Sahagun Sanchez
Hernandez, Eduardo Franco
Quiroz, Felipe Flores
Flores, Marilu Najera
Vicencio, Andrea Jimena Cuevas
Ahlstrom, Jennifer M.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[30] Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
Shah, Jatin J.
Feng, Lei
Manasanch, Elisabet E.
Weber, Donna M.
Thomas, Sheeba K.
Turturro, Francesco
Alexanian, Raymond
Shah, Nina
Popat, Uday R.
Nieto, Yago
Bashir, Qaiser
Qazilbash, Muzaffar H.
Champlin, Richard E.
Orlowski, Robert Z.
BLOOD, 2014, 124 (21)

← 1 2 3 4 5 →